A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension
- PMID: 23264720
- PMCID: PMC3527842
A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension
Abstract
Pulmonary arterial hypertension (PAH) is a life-threatening disease whose prognosis has changed dramatically over the past decade since the introduction of new therapeutic agents as well as the off-label application of adult pulmonary hypertension specific therapies to children. Nevertheless, PAH still has no cure and the aim of treatment is to prolong survival by improving quality of life, symptoms, exercise capacity and hemodynamics. The selection of appropriate therapies for PH is complex and must be carefully chosen according to the etiology and pulmonary vasoreactivity. As insight advances into mechanisms responsible for the development of PAH, the introduction of novel therapeutic agents will hopefully further improve the outcome of this incurable disease.
References
-
- Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–S54. - PubMed
-
- van Loon RL, Roofthooft MT, van Osch-Gevers M, et al. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr. 2009;155:176–182. e1. - PubMed
-
- Rosenzweig EB, Barst RJ. Pulmonary arterial hypertension in children: a medical update. Indian J Pediatr. 2009;76:77–81. - PubMed
-
- Beghetti M, Tissot C. Pulmonary arterial hypertension in congenital heart diseases. Semin Respir Crit Care Med. 2009;30:421–428. - PubMed
-
- Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006. Heart. 2009;95:312–317. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous